Trial Profile
A Phase I and Enrichment Study of Low-dose Metronomic Topotecan and Pazopanib in Pediatric Patients With Recurrent or Refractory Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jun 2022
Price :
$35
*
At a glance
- Drugs Topotecan (Primary) ; Pazopanib
- Indications Neuroblastoma; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions
- Acronyms TOPAZ
- 27 Jun 2022 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 16 Mar 2020 Planned number of patients changed from 42 to 66.